For metastatic pancreatic cancer, is there a role for maintenance chemotherapy if patient has stable disease at the end of 12 cycles of dose reduced modified FOLFIRINOX?

How would you approach this situation in the absence of BRCA mutation data?

Answer from: Medical Oncologist at Academic Institution

Although the original FOLFIRINOX data (Conroy, NEJM, 2011) evaluated efficacy of a six-month course of treatment in patients with metastatic pancreatic cancer, few of us would feel comfortable discontinuing chemotherapy entirely for these patients at the end of a six month period. In the absen...

Comments

Medical Oncologist at Los Angeles VA Medical Center
I've seen similar approaches to Dr. Reiss Binder's...

Please select the option that best describes you:

For metastatic pancreatic cancer, is there a role for maintenance chemotherapy if patient has stable disease at the end of 12 cycles of dose reduced modified FOLFIRINOX?

Related Questions